RxDoctor Payments Data

Christina Hicks, APRN

Women's Health · Dallas, TXNPI 1477942043

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $6,608 of the $8,102 with a category attached, or 81.6%. Coloplast accounts for 65.0% of it on its own, with 6 other manufacturers making up the rest. 2025 is the largest year on record at $4,300, more than ten times the $181 reported in 2021. Among women's health clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$8,102in general payments, 2019–2025

Across 40 payments — averaging $202.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coloplast$5K
  • Sumitomo Pharma America, Inc.$1K
  • Medtronic$463
  • Urovant Sciences Inc$380
  • Astellas Pharma US Inc$283
  • Convatec Inc.$161
  • plus $121 from 1 others

What the payments were for

  • Consulting fees$6,60882%
  • Travel & lodging$1242%
  • Food & beverage$1,36417%
  • Education$50%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,102 in reported general payments places this provider in the 95th percentile of 609 women's health providers in Texas.

See all women's health providers in Texas

Medicare billing

Part B allowed, 2024
$63,283
Medicare patients
245
Services billed
886

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron97$76,065
MyrbetriqMirabegron48$33,766
Estradiol224$14,056
PremarinEstrogens, Conjugated17$7,659
Mirabegron ErMirabegron12$6,820
Methenamine Hippurate26$2,432
Clindamycin Phosphate17$1,312
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst79$1,107
Solifenacin Succinate23$1,059
NitrofurantoinNitrofurantoin Macrocrystal18$1,032
Cephalexin73$1,029
Baclofen35$894
Terconazole34$871
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip21$803
ProgesteroneProgesterone, Micronized16$671

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$1,425$76,06597 claims
Astellas Pharma US IncMyrbetriq$283$33,76648 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 609 women's health providers in Texas.

Other women's health in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →